-transparent.png){kind=logo}
D-penicillamine is a potent drug used to treat rheumatoid arthritis, Wilson's disease and cystinuria. D-penicillamine has recently been found to cause myasthenia gravis in certain susceptible patients. We present a typical case of one patient who developed myasthenia while taking D-penicillamine. The withdrawal of D-penicillamine and the institution of short-term anticholinesterase therapy resulted in the resolution of this disease. The literature is reviewed and attention is focused on the point that all patients who developed myasthenia while undergoing D-penicillamine therapy had ocular symptoms.
Related Publications
R L Kimbrough, and
L Mewis, and
R H Stewart
January 1984,
Zeitschrift fur arztliche Fortbildung,
R L Kimbrough, and
L Mewis, and
R H Stewart
November 1987,
Bulletin des societes d'ophtalmologie de France,
R L Kimbrough, and
L Mewis, and
R H Stewart
December 1980,
La Nouvelle presse medicale,
R L Kimbrough, and
L Mewis, and
R H Stewart
January 1977,
Annales de medecine interne,
R L Kimbrough, and
L Mewis, and
R H Stewart
February 1978,
Klinische Wochenschrift,
R L Kimbrough, and
L Mewis, and
R H Stewart
January 1978,
Bulletin de la Societe belge d'ophtalmologie,
R L Kimbrough, and
L Mewis, and
R H Stewart
May 1982,
La Nouvelle presse medicale,
R L Kimbrough, and
L Mewis, and
R H Stewart
July 2002,
Klinische Monatsblatter fur Augenheilkunde,
R L Kimbrough, and
L Mewis, and
R H Stewart
December 1989,
The British journal of ophthalmology,
R L Kimbrough, and
L Mewis, and
R H Stewart
December 1978,
Annals of internal medicine,
